SciClone Pharmaceuticals, Inc. (SCLN) Given a $14.00 Price Target at Maxim Group

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has been assigned a $14.00 price target by research analysts at Maxim Group in a note issued to investors on Thursday, May 11th. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Maxim Group’s target price would indicate a potential upside of 27.85% from the company’s previous close.

The analysts wrote, “SciClone reported 1Q17 results with total revenues of $43M, slightly down sequentially but up 17.5% YoY, driven principally by ZADAXIN. Net income for the quarter was $14.6M or $0.28 per share. SciClone ended the period with $141M of cash on the balance sheet.””

SciClone Pharmaceuticals (NASDAQ SCLN) opened at 10.95 on Thursday. The company has a 50 day moving average price of $9.88 and a 200-day moving average price of $9.98. SciClone Pharmaceuticals has a 52 week low of $8.55 and a 52 week high of $13.99. The firm has a market capitalization of $566.47 million, a price-to-earnings ratio of 15.40 and a beta of 1.76.

WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/06/17/maxim-group-analysts-give-sciclone-pharmaceuticals-inc-scln-a-14-00-price-target-updated-updated-updated.html.

In other SciClone Pharmaceuticals news, CFO Wilson Wai-Shun Cheung sold 40,500 shares of SciClone Pharmaceuticals stock in a transaction on Monday, June 12th. The stock was sold at an average price of $10.75, for a total value of $435,375.00. Following the completion of the transaction, the chief financial officer now directly owns 14,372 shares of the company’s stock, valued at approximately $154,499. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Friedhelm Blobel sold 40,000 shares of SciClone Pharmaceuticals stock in a transaction on Wednesday, March 22nd. The shares were sold at an average price of $9.47, for a total value of $378,800.00. Following the completion of the transaction, the chief executive officer now directly owns 122,864 shares of the company’s stock, valued at $1,163,522.08. The disclosure for this sale can be found here. Insiders sold a total of 233,082 shares of company stock valued at $2,318,084 over the last 90 days. 7.63% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of SCLN. Municipal Employees Retirement System of Michigan boosted its position in SciClone Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 47,180 shares of the specialty pharmaceutical company’s stock worth $483,000 after buying an additional 120 shares during the period. New York State Teachers Retirement System boosted its position in SciClone Pharmaceuticals by 0.7% in the fourth quarter. New York State Teachers Retirement System now owns 40,921 shares of the specialty pharmaceutical company’s stock worth $442,000 after buying an additional 300 shares during the period. Louisiana State Employees Retirement System boosted its position in SciClone Pharmaceuticals by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 21,000 shares of the specialty pharmaceutical company’s stock worth $206,000 after buying an additional 500 shares during the period. Arizona State Retirement System boosted its position in SciClone Pharmaceuticals by 1.9% in the first quarter. Arizona State Retirement System now owns 26,800 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 500 shares during the period. Finally, Mason Street Advisors LLC boosted its position in SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 881 shares during the period. 71.88% of the stock is owned by institutional investors.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

What are top analysts saying about SciClone Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SciClone Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit